Policy Statements
The American Society of Hematology represents the interests of hematologists and their patients before Congress and the Executive branch, advocating for the best science and practice of hematology. When warranted, ASH issues policy statements on research, practice, training, or quality of care issues that are likely to have an impact on the field.
Statement in Support of the Value of Scholarly Publishers
As a member of the Council of Medical Specialty Societies (CMSS) and an organization committed to promoting and supporting clinical and scientific research in hematology, the American Society of Hematology (ASH) supports the CMSS statement on the val...
Read moreASH Position on Sickle Cell Trait
ASH Position It is medically inaccurate to claim sickle cell crisis as the cause of death based solely on the presence of sickled cells at autopsy. Sudden death is an extraordinarily rare occurrence in sickle cell trait and the finding of sickle cell...
Read moreAccess to Hematology Care in an Age of Innovation
The American Society of Hematology (ASH) believes that all individuals should have access to and be able to afford high-quality, clinically appropriate care, including innovative therapeutics. Hematologists treat patients with malignant hematologic d...
Read moreASH Statement in Support of Palliative Blood Transfusions in Hospice Setting
The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. As an organization of physicians and scientists who care f...
Read moreStatement on Opioid Use in Patients with Hematologic Diseases and Disorders
The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study of blood and treatment of blood-related diseases. ASH members include clinicians who specialize in treating c...
Read moreASH Policy Statement in Support of Patient Access to Safe and Effective Drugs
ASH Policy Statement in Support of Patient Access to Safe and Effective DrugsAs an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, as well as...
Read moreStatement on Screening for Sickle Cell Trait and Athletic Participation
Background The American Society of Hematology (ASH) represents approximately 16,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. ASH members include clinicians who specialize i...
Read moreFrequently Asked Questions Regarding Sickle Cell Trait
Sickle cell trait is an inherited blood disorder affects approximately 8 percent of African-Americans. Unlike sickle cell disease, a serious illness in which patients have two genes that cause the production of abnormal hemoglobin, ind...
Read moreStatement in Support of All Avenues of Stem Cell Research
As an organization of physicians who care for desperately ill patients and scientists devoted to understanding the basic mechanisms of disease and discovering new therapies, the American Society of Hematology (ASH) is excited about the scientific pot...
Read moreStatement on Clinical Research and Trials
Clinical research in hematology has never been more important, yet clinical hematology investigators are facing unprecedented challenges. Constantly changing and often inconsistent regulations, chaotic reimbursement policies, lack of insurance covera...
Read more- 1
- 2